Chronic heart disease and Anaemia

Heart failure is a very common disease, with severe morbidity and mortality, and is a frequent reason of hospitalization. Anemia and a concurrent renal impairment are two major risk factors contributing to the severity of the outcome.

Chronic heart disease and Anaemia

Anemia in heart failure is complex and multifactorial. Hemodilution, absolute or functional iron deficiency, activation of the inflammatory cascade, and impaired erythropoietin production and activity are some pathophysiological mechanisms involved in anemia of heart failure

Chronic heart disease and Anaemia

Cardiovascular diseases are among the most frequent causes of death worldwide. Heart failure is an enormous medical and societal burden and a leading cause of hospitalization. It is estimated that 2.6 millions hospitalizations annually in the USA are due to heart failure as a primary or secondary diagnosis.

Chronic heart disease and Anaemia

Anemia is common in patients with heart disease. It is present in approximately one third of patients with congestive heart failure (CHF) and 10% to 20% of patients with coronary heart disease (CHD)

More than one-quarter of the world's population is anemic. Approximately one-half of this burden is a result of iron deficiency anemia, being most prevalent among preschool children and women. The diagnosis, prevention, and treatment of iron deficiency is obviously a major public health goal, especially in low- and middle-income countries.

Chronic heart disease and Anaemia

Chronic heart disease and Anaemia

Anemia of chronic inflammation is the most common cause of anemia and occurs in 58% of heart failure patients with anemia. Anemia of inflammation and chronic disease is a type of anemia that commonly occurs with chronic, or long term, illnesses or infections.

Solution

The absorption of heme iron is several times higher and the side-effects rate significantly lower than for non-heme oral iron. Heme iron is absorbed through a separate pathway and does not have to be discontinued when intravenous treatment is started. This can allow for longer intervals between resource-heavy, inconvenient and painful injections. Oxidative stress is also avoided.Heme iron does not need to be discontinued during injection or EPO therapy like non-heme oral iron.

OptiFer®

The OptiFer® series of iron food supplements are safe, efficient and very well tolerated, which is crucial for therapy success.They can be used over longer periods with no change in efficacy or tolerance.